Strides Pharma Science Limited (Strides) on Thursday announced that it has appointed R Ananthanarayanan as Chief Executive Officer (CEO) and Managing Director (MD). His appointment has been approved by the BoD (Board of Directors) and will be effective from January 09, 2020.
R Ananthanarayanan (Ananth) will succeed Arun Kumar, Founder, and the incumbent CEO & MD of the Company. Arun will transition his active responsibilities at Strides by the financial year ending March 31, 2020, and will step into a strategic role as Chairman of the Board with effect from April 01, 2020.
Before joining Strides, Ananth was associated with Cipla. He was the Global Chief Operating Officer at Cipla Limited and was responsible for the company’s generics business in regulated markets and branded generics in emerging markets. Ananth is a Graduate in Pharmaceutical Sciences and earned his Ph.D. in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey.
Prior to Cipla, Ananth was the President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the US, managing multi-billion P&L responsibility. He has also held leadership roles at Dr. Reddy’s Laboratories, Piramal Healthcare (Formerly Nicholas Piramal), Galpharm International, UK (Acquired by Perrigo Group), and Zydus Cadila.
Strides Founder Arun Kumar said, “Having founded Strides and led the company for close to 30 years, I believe the time is right for me to step aside and have Ananth lead it to greater heights. Ananth brings in the right balance of technical and commercial expertise, and I am confident that Strides will significantly benefit from his leadership experience, industry perspective, technical knowledge, and business acumen. As he takes on the mantle of Strides, I will now move to a more strategic role as the Chairman of the Board and will dedicate time to Strides’ newly announced investments in Biotech and sterile injectables.”
R Ananthanarayanan, the new CEO & MD of Strides, said, “It’s my privilege and honor to take over as the CEO &MD of Strides, and I would like to appreciate the confidence reposed in me by Arun and the Board. These are exciting times for Strides, and I look forward to partner with all the global colleagues to ensure successful realization of the Strides strategic objectives while ensuring that we consistently deliver quality medicines to all our patients globally.”